Launch of TerugBetaalRegeling Broxil®
The health insurer does not fully reimburse Broxil® 125 mg / 5 mL, powder for oral suspension. The producer of this medicine has therefore asked TBR Nederland to reimburse the costs of the Personal Contribution to the patient.
The Personal Contribution for Broxil® 125 mg / 5 mL, powder for oral suspension that is demonstrably charged to the patient by the health insurer will be fully reimbursed from 1 Augustus 2020 up to a maximum of € 250 per patient per year. The arrangement is limited to patients who are dependent on this drug for (functional) asplenia or recurrent erysipelas. To be eligible, a Doctor's statement completed by the specialist is required.
Who can submit a claim
Only patients or their carer can submit a claim for the Personal Contribution paid for Broxil® 125 mg / 5 mL, powder for oral suspension online or by post. Online will be the fastest option. Pharmacists cannot submit claims for this medicine on behalf of the patient.
For more information check out the Broxil® 125 mg / 5 mL, powder for oral suspension Medicine page